$-0.07
(Market cap
$70 Mln
Recently Viewed
Clear AllMarket cap
$70 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-53 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
36,150,800
CFO
$-150.16 Mln
EBITDA
$-227.06 Mln
Net Profit
$-228.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cortexyme (CRTX)
| -89.5 | -22.7 | -41.2 | -98.6 | -62.2 | -- | -- |
|
BSE Sensex*
| -8.5 | 5.3 | -5.9 | -3.4 | 8.2 | 9.3 | 11.7 |
|
Company
|
2021
|
2020
|
|---|---|---|
|
Cortexyme (CRTX)
| -54.6 | -50.5 |
|
BSE Sensex
| 22.0 | 15.8 |
|
BSE Sensex
| 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cortexyme (CRTX)
|
1.3 | 70.5 | 0.0 | -136.1 | -- | -129.8 | -- | 0.7 |
| 70.1 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 60.7 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 83.1 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 63.9 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 516.7 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 409.7 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 101.9 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 321.9 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule... gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Read more
Exec. VP of R&D
Dr. Leslie J. Holsinger Ph.D.
Exec. VP of R&D
Dr. Leslie J. Holsinger Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cortexyme Inc (CRTX) is $1.33 (NASDAQ) as of 30-Sep-2022 09:30 EDT. Cortexyme Inc (CRTX) has given a return of -62.21% in the last 3 years.
Since, TTM earnings of Cortexyme Inc (CRTX) is negative, P/E ratio is not available.
The P/B ratio of Cortexyme Inc (CRTX) is 0.66 times as on 30-Sep-2022, a 85 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Cortexyme Inc (CRTX) are Rs -- and Rs -- as of 29-Apr-2026.
Cortexyme Inc (CRTX) has a market capitalisation of $ 70 Mln as on 30-Sep-2022. As per SEBI classification, it is a company.
Before investing in Cortexyme Inc (CRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.